Congenital primary megaureter is a developmental anomaly of the distal ureter in which a short, non-dilated segment immediately above the ureterovesical junction (the juxtavesical/intramural segment) is intrinsically aperistaltic: an abnormal circular-to-longitudinal smooth muscle fiber ratio and excess interposed collagen disrupt the muscular continuity required to propagate a peristaltic wave, so the segment fails to actively transport the urine bolus across the ureterovesical junction. The bladder and bladder outlet are normal. Because this is an intrinsic lesion of the ureteric wall itself rather than a fixed anatomic stricture or a bladder-outlet problem, primary megaureter is defined by exclusion of secondary causes of ureteral dilation (posterior urethral valves, neurogenic bladder, extrinsic compression, or high-grade reflux from an unrelated cause). Within primary megaureter, the same aperistaltic segment can differentially produce a functional (dynamic) impediment to antegrade urine transport and/or coincide with a separate, shortened intravesical ureteric tunnel that renders the ureterovesical junction incompetent to reflux — so the Smith/King classification divides primary megaureter into four forms according to whether obstruction and/or reflux accompany the aperistaltic segment: obstructed, refluxing, non-obstructed and non-refluxing (the commonest form, usually detected antenatally or incidentally and managed conservatively because most resolve or stabilize with growth), and combined obstructed-and-refluxing. Chronic impaired antegrade bolus transport, with or without reflux, produces progressive proximal ureteral dilation and elongation (megaureter) that can transmit back-pressure and stasis to the collecting system, causing hydroureteronephrosis; sustained high-grade cases risk recurrent urinary tract infection and, uncommonly, progressive renal impairment. Primary megaureter sits within the broader congenital anomalies of the kidney and urinary tract (CAKUT) spectrum alongside vesicoureteral reflux and ureteropelvic junction obstruction.
Ask a research question about Congenital Primary Megaureter. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Congenital Primary Megaureter
creation_date: "2026-08-26T00:00:00Z"
category: Congenital
disease_term:
preferred_term: congenital primary megaureter
term:
id: MONDO:0018960
label: congenital primary megaureter
synonyms:
- congenital giant megaureter
- congenital megalo-ureter
- congenital primary megalo-ureter
- CGM
parents:
- kidney disorder
- disorder of development or morphogenesis
- congenital anomaly of the kidney and urinary tract (CAKUT)
description: >
Congenital primary megaureter is a developmental anomaly of the distal ureter
in which a short, non-dilated segment immediately above the ureterovesical
junction (the juxtavesical/intramural segment) is intrinsically aperistaltic:
an abnormal circular-to-longitudinal smooth muscle fiber ratio and excess
interposed collagen disrupt the muscular continuity required to propagate a
peristaltic wave, so the segment fails to actively transport the urine bolus
across the ureterovesical junction. The bladder and bladder outlet are
normal. Because this is an intrinsic lesion of the ureteric wall itself
rather than a fixed anatomic stricture or a bladder-outlet problem, primary
megaureter is defined by exclusion of secondary causes of ureteral dilation
(posterior urethral valves, neurogenic bladder, extrinsic compression, or
high-grade reflux from an unrelated cause). Within primary megaureter, the
same aperistaltic segment can differentially produce a functional (dynamic)
impediment to antegrade urine transport and/or coincide with a separate,
shortened intravesical ureteric tunnel that renders the ureterovesical
junction incompetent to reflux — so the Smith/King classification divides
primary megaureter into four forms according to whether obstruction and/or
reflux accompany the aperistaltic segment: obstructed, refluxing,
non-obstructed and non-refluxing (the commonest form, usually detected
antenatally or incidentally and managed conservatively because most resolve
or stabilize with growth), and combined obstructed-and-refluxing. Chronic
impaired antegrade bolus transport, with or without reflux, produces
progressive proximal ureteral dilation and elongation (megaureter) that can
transmit back-pressure and stasis to the collecting system, causing
hydroureteronephrosis; sustained high-grade cases risk recurrent urinary
tract infection and, uncommonly, progressive renal impairment. Primary
megaureter sits within the broader congenital anomalies of the kidney and
urinary tract (CAKUT) spectrum alongside vesicoureteral reflux and
ureteropelvic junction obstruction.
notes: >
Scope: this entry models the four congenital ("infantile-onset") Smith/King
forms of PRIMARY megaureter — obstructed, refluxing, non-obstructed and
non-refluxing, and combined obstructed-and-refluxing — corresponding to
MONDO:0016550, MONDO:0016551, MONDO:0016552, and MONDO:0035295 respectively.
A distinct, separately MONDO-coded adult-onset form (primary megaureter,
adult-onset form, MONDO:0016549) is out of scope here. SECONDARY megaureter
(posterior urethral valves, neurogenic/non-neurogenic voiding dysfunction,
prune-belly syndrome, or high-grade reflux from a defined syndromic cause) is
likewise out of scope and belongs on the respective causative entry; the
defining feature of "primary" megaureter is that the ureteral wall lesion is
intrinsic and the bladder/bladder outlet are normal. This entry is
cross-referenced to Familial_Vesicoureteral_Reflux.yaml, which models
primary VUR arising from an isolated incompetent ureterovesical junction
without an aperistaltic segment or ureteral dilation as its defining lesion —
the "refluxing" and "combined" forms of primary megaureter here additionally
require the aperistaltic segment plus ureteral dilation, distinguishing them
from familial VUR.
references:
- reference: PMID:24206785
title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
- reference: PMID:11387761
title: "Megaureter: classification, pathophysiology, and management."
- reference: PMID:38441661
title: "Primary non-refluxing megaureter: Natural history, follow-up and treatment."
- reference: PMID:22397575
title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
- reference: PMID:17301719
title: "C-kit positive interstitial cells of Cajal network in primary obstructive megaureter."
- reference: PMID:34315317
title: "Telocytes, c-Kit positive cells, Smooth muscles, and collagen in the ureter of pediatric patients with congenital primary obstructive megaureter: elucidation of etiopathology."
- reference: PMID:9610598
title: "A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood."
- reference: PMID:15665928
title: "Contractile function of the smooth-muscle wall and its adrenergic regulation in megaureter."
- reference: PMID:37961019
title: "Peristalsis prevents ureteral dilation."
- reference: PMID:30345263
title: "Long-Term Outcomes in Primary Obstructive Megaureter Treated by Endoscopic Balloon Dilation. Experience After 100 Cases."
- reference: PMID:38954357
title: "Advancements in Surgical Management of Megaureters."
- reference: PMID:31968361
title: "[Primary megaureter in the newborn period: making the case for a temporary splint-free cutaneous ureterostomy]."
- reference: PMID:29937413
title: "Outcome of end cutaneous ureterostomy (ECU) as a non conservative option in the management of primary obstructive megaureters (POM)."
- reference: PMID:39076761
title: "Congenital anomalies of the kidney and urinary tract."
- reference: clinicaltrials:NCT05639283
title: "Primary Obstructive Megaureter Management in Eastern Interregional Area : Current Status and Perspectives"
has_subtypes:
- name: Obstructed
display_name: Obstructed primary megaureter
description: >
The aperistaltic juxtavesical segment functionally impedes antegrade urine
bolus transport (a dynamic, not a fixed anatomic, obstruction) without
reflux, producing progressive proximal ureteral dilation and, in more
severe or bilateral cases, hydroureteronephrosis and risk of impaired
differential renal function.
subtype_term:
preferred_term: congenital primary megaureter, obstructed form
term:
id: MONDO:0016550
label: congenital primary megaureter, obstructed form
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Indications for surgical intervention include symptoms such as febrile UTIs or pain, and in the asymptomatic patient, a DRF below 40% associated with massive or progressive hydronephrosis, or a drop in differential function on serial renograms."
explanation: >-
Supports that the obstructed form risks progressive hydronephrosis and
impaired differential renal function that may require surgical
correction.
- name: Refluxing
display_name: Refluxing primary megaureter
description: >
The aperistaltic segment coincides with a separate, shortened intravesical
(submucosal) ureteric tunnel that renders the ureterovesical junction
incompetent, producing vesicoureteral reflux in addition to the primary
ureteral dilation from impaired antegrade transport.
subtype_term:
preferred_term: congenital primary megaureter, refluxing form
term:
id: MONDO:0016551
label: congenital primary megaureter, refluxing form
evidence:
- reference: PMID:9610598
reference_title: "A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Refluxing megaureters contained only 55% +/- 15% type I collagen. However, there was an increase in type III collagen (16% +/- 4%) versus (4.5% +/- 2%) in controls (P <0.05)."
explanation: >-
Quantitative histology shows the refluxing form has a distinct collagen
subtype composition (relatively more type III collagen) compared with
the obstructed form, a stiffer, less distensible fiber associated with
lower surgical reimplantation success in the source study.
- name: Non-obstructed Non-refluxing
display_name: Non-obstructed, non-refluxing primary megaureter
description: >
The commonest form: the aperistaltic segment produces ureteral dilation
without a demonstrable functional obstruction or reflux. Most cases are
detected antenatally or incidentally, remain stable or improve with growth
of the ureter and resolution of the relative caliber mismatch across the
segment, and are managed with observation rather than surgery.
subtype_term:
preferred_term: congenital primary megaureter, nonrefluxing and unobstructed form
term:
id: MONDO:0016552
label: congenital primary megaureter, nonrefluxing and unobstructed form
evidence:
- reference: PMID:38441661
reference_title: "Primary non-refluxing megaureter: Natural history, follow-up and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PMU is the result of an atonic or stenotic segment of the distal ureter, resulting in congenital dilation of the ureter, and is frequently diagnosed on routine antenatal ultrasound."
explanation: >-
Supports the atonic (aperistaltic) distal ureteric segment mechanism
and typical antenatal detection of the non-obstructed non-refluxing
form.
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In total, 72 PM were identified in this series. At the end of the follow-up period, 38 PM (52.8%) had resolved, in 18 PM (25%) ureteral dilatation persisted and 16 PM (22.2%) required a surgical procedure."
explanation: >-
Long-term follow-up of neonatally diagnosed primary megaureter shows
that more than half resolve spontaneously, supporting the conservative
management approach for this commonest form.
- name: Combined Obstructed and Refluxing
display_name: Combined obstructed-and-refluxing primary megaureter
description: >
The aperistaltic segment both functionally impedes antegrade transport and
coincides with an incompetent ureterovesical junction, so obstruction and
reflux co-occur; this form carries the greatest risk of progressive
hydroureteronephrosis, recurrent urinary tract infection, and renal injury,
and most often requires surgical correction.
subtype_term:
preferred_term: congenital primary megaureter, refluxing and obstructed form
term:
id: MONDO:0035295
label: congenital primary megaureter, refluxing and obstructed form
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Indications for surgical intervention include symptoms such as febrile UTIs or pain, and in the asymptomatic patient, a DRF below 40% associated with massive or progressive hydronephrosis, or a drop in differential function on serial renograms."
explanation: >-
Supports that combined obstruction and reflux carries risk of
progressive hydronephrosis and impaired differential renal function
requiring surgical correction.
prevalence:
- population: Antenatally detected hydronephrosis/urinary tract dilation cohorts
measure_type: UNKNOWN
prevalence_class: UNKNOWN
notes: >-
Population-level birth prevalence for primary megaureter is not
established in the literature. What is reported is its share of another,
broader condition category (antenatally detected hydronephrosis/urinary
tract dilation), not a standalone population rate, so no
rate_per_100000 is given here.
evidence:
- reference: PMID:38441661
reference_title: "Primary non-refluxing megaureter: Natural history, follow-up and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Primary non-refluxing megaureter (PMU) is a congenital dilation of the ureter which is not related to vesicoureteral reflux, duplicated collecting systems, ureterocele, ectopic ureter, or posterior urethral valves and accounts for 5 to 10% of all prenatal hydronephrosis (HN) cases."
explanation: >-
Quantifies primary non-refluxing megaureter as 5-10% of all prenatal
hydronephrosis cases.
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Primary megaureter (PM) represents 6-10% of all antenatal displaced urinary malformations."
explanation: >-
An independent series similarly quantifies primary megaureter as 6-10%
of antenatally detected urinary tract malformations.
pathophysiology:
- name: Aperistaltic Juxtavesical Ureteric Segment
description: >
A short segment of ureter immediately proximal to the ureterovesical
junction shows an abnormal circular-to-longitudinal smooth muscle fiber
ratio together with excess interposed collagen deposition between and
around the muscle bundles. This disrupted muscular architecture prevents
the coordinated, wavelike smooth muscle contraction required to propagate
a peristaltic wave, so the segment cannot actively transport the urine
bolus across the ureterovesical junction even though it is not narrowed
(not a fixed anatomic stricture). This lesion is common to all four
Smith/King forms of primary megaureter.
biological_scale: TISSUE
cell_types:
- preferred_term: ureter smooth muscle cell
term:
id: CL:1000979
label: ureter smooth muscle cell
biological_processes:
- preferred_term: ureteric peristalsis
modifier: ABSENT
term:
id: GO:0072105
label: ureteric peristalsis
- preferred_term: collagen fibril organization
modifier: INCREASED
term:
id: GO:0030199
label: collagen fibril organization
locations:
- preferred_term: ureterovesical junction
term:
id: UBERON:0009973
label: ureterovesical junction
evidence:
- reference: PMID:17301719
reference_title: "C-kit positive interstitial cells of Cajal network in primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Marked muscle hypoplasia and sparse or no ICCs occurred in the longitudinal muscle layer of the restricted ureteral segments."
explanation: >-
Surgical specimens of primary obstructive megaureter show the muscular
abnormality is confined to the longitudinal muscle layer of the
restricted (aperistaltic) segment, supporting an abnormal
circular-to-longitudinal muscle architecture at this site.
- reference: PMID:34315317
reference_title: "Telocytes, c-Kit positive cells, Smooth muscles, and collagen in the ureter of pediatric patients with congenital primary obstructive megaureter: elucidation of etiopathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Obstructed segment showed excess collagen intervening between smooth muscles, excess c-Kit positive cells, and presence of telocytes."
explanation: >-
Histology of the aperistaltic (obstructed) segment demonstrates excess
collagen deposited between smooth muscle bundles, directly supporting
the excess collagen component of the mechanism.
- reference: PMID:34315317
reference_title: "Telocytes, c-Kit positive cells, Smooth muscles, and collagen in the ureter of pediatric patients with congenital primary obstructive megaureter: elucidation of etiopathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the obstructed segment had no muscle conductivity due to excess collagen irrespective of presence of telocytes"
explanation: >-
Links the excess interposed collagen directly to loss of muscular
conductivity, the mechanism by which the segment fails to propagate a
peristaltic wave.
- reference: PMID:9610598
reference_title: "A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Immunohistochemical studies demonstrated increases in collagen types I and III for both obstructed and refluxing megaureters compared with controls (P <0.05)."
explanation: >-
A quantitative immunohistochemical study confirms increased collagen
content in the ureteral wall of both obstructed and refluxing primary
megaureter compared with normal control ureters.
downstream:
- target: Impaired Antegrade Ureteral Bolus Transport
causal_link_type: DIRECT
description: >
Because the aperistaltic segment cannot generate a propagating
contraction, urine boluses delivered from the normally peristaltic
proximal ureter are not actively propelled across the segment,
producing a functional (dynamic) impediment to antegrade urine flow
distinct from a fixed anatomic narrowing.
- target: Ureterovesical Junction Incompetence
causal_link_type: DIRECT
description: >
In the refluxing and combined obstructed-and-refluxing forms only, the
same distal ureteric region also carries a separate, shortened
intravesical (submucosal) ureteric tunnel, analogous to the lesion of
isolated primary vesicoureteral reflux, rendering the ureterovesical
valve mechanism incompetent. This edge does not apply to the obstructed
or non-obstructed non-refluxing forms.
- name: Impaired Antegrade Ureteral Bolus Transport
description: >
The functional (dynamic) impediment to antegrade urine transport across
the aperistaltic segment, present to some degree whenever the segment
fails to propagate a peristaltic wave. In the obstructed and combined
forms this impediment is clinically significant enough to be classified
as (functional) obstruction; in the non-obstructed non-refluxing form the
impediment is mild and does not meet criteria for obstruction.
biological_scale: TISSUE
evidence:
- reference: PMID:15665928
reference_title: "Contractile function of the smooth-muscle wall and its adrenergic regulation in megaureter."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "The rhythmic and tonic contractions were suppressed in the megaureters with organic obstruction in comparison with megaureters caused by reflux."
explanation: >-
Ex vivo organ-bath contractility testing of excised ureteral wall shows
suppressed rhythmic and tonic contractile activity in obstructed
megaureter, supporting impaired muscular transport of the urine bolus.
downstream:
- target: Ureteral Dilation (Megaureter)
causal_link_type: DIRECT
description: >
Urine accumulating proximal to the poorly transporting segment
progressively dilates and elongates the ureter above it.
evidence:
- reference: PMID:37961019
reference_title: "Peristalsis prevents ureteral dilation."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "We theorize that this retrograde flow can lead to urinary stasis and urine accumulation in the ureters, resulting in ureteral dilation seen on imaging studies and elevated infection risk."
explanation: >-
A mathematical model of ureteral peristalsis supports that abnormal
(insufficient-amplitude or non-propagating) peristalsis leads to
urine stasis and accumulation, producing the ureteral dilation seen
on imaging.
- name: Ureterovesical Junction Incompetence
description: >
In the refluxing and combined obstructed-and-refluxing forms, the
ureterovesical junction fails to prevent retrograde urine flow during
bladder filling and voiding — the feature that classifies these two
forms as "refluxing" in the Smith/King scheme, distinct from the
obstructed and non-obstructed non-refluxing forms. The valve-incompetence
mechanism is presumed analogous to that described for isolated primary
vesicoureteral reflux (a shortened, poorly supported intravesical
ureteric tunnel; see Familial_Vesicoureteral_Reflux.yaml), but this has
not been independently confirmed histologically in megaureter
specifically — a knowledge gap rather than an established finding.
biological_scale: TISSUE
locations:
- preferred_term: ureterovesical junction
term:
id: UBERON:0009973
label: ureterovesical junction
evidence:
- reference: PMID:11387761
reference_title: "Megaureter: classification, pathophysiology, and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "refluxing megaureter, associated with vesicoureteral reflux (VUR)"
explanation: >-
Establishes that a ureterovesical-junction reflux process is a
recognized, classified feature of the refluxing (and, by extension,
combined) form of primary megaureter, distinct from the obstructed and
non-obstructed non-refluxing forms.
downstream:
- target: Vesicoureteral Reflux
causal_link_type: DIRECT
description: >
An incompetent ureterovesical valve mechanism allows retrograde flow of
urine from the bladder into the dilated ureter during filling and
voiding.
- name: Vesicoureteral Reflux
description: >
Retrograde flow of urine from the bladder into the ureter (and, in
higher-grade cases, into the renal pelvis and collecting ducts) through
the incompetent ureterovesical junction, compounding the dilation already
produced by impaired antegrade transport. Present only in the refluxing
and combined obstructed-and-refluxing forms.
biological_scale: ORGANISM
evidence:
- reference: PMID:11387761
reference_title: "Megaureter: classification, pathophysiology, and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "refluxing megaureter, associated with vesicoureteral reflux (VUR)"
explanation: >-
Establishes vesicoureteral reflux as the defining additional feature of
the refluxing form of primary megaureter within the accepted
classification scheme.
downstream:
- target: Hydroureteronephrosis
causal_link_type: DIRECT
description: >
Reflux superimposed on impaired antegrade transport increases the
volume and back-pressure of retained urine transmitted to the upper
tract.
- name: Ureteral Dilation (Megaureter)
description: >
Progressive proximal dilation, elongation, and tortuosity of the ureter
above the aperistaltic segment, the defining structural lesion
("megaureter") common to all four forms, differing in degree according to
whether functional obstruction and/or reflux accompany it.
biological_scale: TISSUE
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The BAPU defined a ureteric diameter over 7 mm as abnormal."
explanation: >-
A national consensus statement establishes the clinical threshold used
to define pathological ureteral dilation (megaureter).
downstream:
- target: Hydroureteronephrosis
causal_link_type: DIRECT
description: >
Chronic dilation and stasis in the ureter transmit back-pressure to the
renal pelvis and calyces, producing hydronephrosis in addition to
hydroureter.
- name: Hydroureteronephrosis
description: >
Dilation of the ureter (hydroureter) together with dilation of the renal
pelvis and calyces (hydronephrosis) resulting from chronic impaired
urinary drainage. Severity ranges from mild and stable (most common in the
non-obstructed non-refluxing form) to progressive, with risk of recurrent
urinary tract infection and, in severe or bilateral high-grade disease,
impaired differential renal function.
biological_scale: ORGANISM
evidence:
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Poor drainage on (99m)Tc-DTPA scan, grade IV-V hydronephrosis and ureteric diameter more than 15.0 mm were statistically significant and independent predictive factors for surgery."
explanation: >-
Long-term follow-up of neonatally diagnosed primary megaureter shows
that high-grade hydronephrosis and poor drainage predict progression
requiring surgical correction, supporting the described severity
spectrum.
phenotypes:
- category: Structural
name: Congenital Megaureter
description: >
Congenital dilation of the ureter, the defining structural finding of this
condition, seen to varying degrees across all four Smith/King forms.
phenotype_term:
preferred_term: Congenital megaureter
term:
id: HP:0008676
label: Congenital megaureter
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38441661
reference_title: "Primary non-refluxing megaureter: Natural history, follow-up and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Primary non-refluxing megaureter (PMU) is a congenital dilation of the ureter which is not related to vesicoureteral reflux, duplicated collecting systems, ureterocele, ectopic ureter, or posterior urethral valves and accounts for 5 to 10% of all prenatal hydronephrosis (HN) cases."
explanation: >-
Confirms congenital ureteral dilation as the defining finding and
quantifies its share of prenatally detected hydronephrosis cases.
- category: Structural
name: Hydroureter
description: >
Dilation of the ureter proximal to the aperistaltic segment, present to
some degree in all forms and pronounced in the obstructed and combined
forms.
phenotype_term:
preferred_term: Hydroureter
term:
id: HP:0000072
label: Hydroureter
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The BAPU defined a ureteric diameter over 7 mm as abnormal."
explanation: >-
A national consensus statement establishes the measured-diameter
threshold that defines hydroureter (megaureter) in this condition.
- category: Structural
name: Hydronephrosis
description: >
Dilation of the renal pelvis and calyces secondary to chronically impaired
ureteral drainage; frequently the presenting antenatal ultrasound finding.
phenotype_term:
preferred_term: Hydronephrosis
term:
id: HP:0000126
label: Hydronephrosis
onset:
onset_category: ANTENATAL
evidence:
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Primary megaureter (PM) represents 6-10% of all antenatal displaced urinary malformations."
explanation: >-
Supports that primary megaureter is frequently detected via antenatal
hydronephrosis screening.
- category: Structural
name: Primary Obstructive Megaureter
subtypes:
- Obstructed
- Combined Obstructed and Refluxing
description: >
Megaureter with functional obstruction at the aperistaltic juxtavesical
segment, without reflux, in the obstructed form (and together with reflux
in the combined form).
phenotype_term:
preferred_term: Primary obstructive megaureter
term:
id: HP:4000035
label: Primary obstructive megaureter
evidence:
- reference: PMID:11387761
reference_title: "Megaureter: classification, pathophysiology, and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "obstructive megaureter, associated with urine flow impairment at the vesicoureteral junction"
explanation: >-
Establishes obstructive megaureter, with urine flow impairment at the
ureterovesical junction, as a distinct recognized subtype.
- category: Structural
name: Vesicoureteral Reflux
subtypes:
- Refluxing
- Combined Obstructed and Refluxing
description: >
Retrograde flow of urine into the ureter through the incompetent
ureterovesical junction, present in the refluxing and combined forms.
phenotype_term:
preferred_term: Vesicoureteral reflux
term:
id: HP:0000076
label: Vesicoureteral reflux
evidence:
- reference: PMID:11387761
reference_title: "Megaureter: classification, pathophysiology, and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "refluxing megaureter, associated with vesicoureteral reflux (VUR)"
explanation: >-
Establishes vesicoureteral reflux as a distinct recognized subtype of
megaureter, alongside the obstructive and non-obstructive
non-refluxing forms.
- category: Clinical
name: Recurrent Urinary Tract Infections
description: >
Urinary stasis from chronic dilation, with or without superimposed
reflux, predisposes to recurrent febrile urinary tract infection, the
most common clinical complication and indication for surgical
correction in higher-grade disease.
phenotype_term:
preferred_term: Recurrent urinary tract infections
term:
id: HP:0000010
label: Recurrent urinary tract infections
frequency: OCCASIONAL
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Indications for surgical intervention include symptoms such as febrile UTIs or pain, and in the asymptomatic patient, a DRF below 40% associated with massive or progressive hydronephrosis, or a drop in differential function on serial renograms."
explanation: >-
A national consensus statement lists febrile urinary tract infection as
a recognized clinical complication and indication for surgery in
primary megaureter.
- category: Structural
name: Renal Parenchymal Thinning
subtypes:
- Obstructed
- Combined Obstructed and Refluxing
description: >
Thinning of the renal cortex/parenchyma from sustained back-pressure and
stasis, an indication for surgical correction rather than continued
observation; reported predominantly in operated cohorts of the
obstructed and combined forms. No `frequency:` is assigned here because
the only quantitative estimates available are drawn from a selected
surgical (operated) cohort rather than the general primary-megaureter
population.
phenotype_term:
preferred_term: Renal cortical thinning
term:
id: HP:0025327
label: Decreased renal parenchymal thickness
evidence:
- reference: PMID:29937413
reference_title: "Outcome of end cutaneous ureterostomy (ECU) as a non conservative option in the management of primary obstructive megaureters (POM)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "one had incidentally diagnosed renal cortical thinning"
explanation: >-
Reports renal cortical thinning as an observed finding in a surgical
series of primary obstructive megaureter.
- category: Clinical
name: Impaired Differential Renal Function
subtypes:
- Obstructed
- Combined Obstructed and Refluxing
description: >
A fall in the affected kidney's differential renal function (DRF) on
diuretic renography, an indication for surgical correction rather than
continued observation; reported predominantly in the obstructed and
combined forms. No `frequency:` is assigned here because the only
quantitative estimates available are drawn from a selected surgical
(operated) cohort rather than the general primary-megaureter population.
phenotype_term:
preferred_term: Impaired differential renal function
term:
id: HP:0000083
label: Renal insufficiency
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a DRF below 40% associated with massive or progressive hydronephrosis, or a drop in differential function on serial renograms"
explanation: >-
A national consensus statement uses a differential-renal-function
threshold and its serial decline as a criterion for surgical
intervention, establishing impaired differential renal function as a
recognized clinical finding in this condition.
progression:
- phase: Non-obstructed non-refluxing form — stabilization or spontaneous resolution
subtype: Non-obstructed Non-refluxing
age_range: Infancy through early childhood (typically resolves within several years of diagnosis)
notes: >-
The commonest form usually stabilizes or resolves without surgery as the
ureter grows and the relative caliber mismatch across the aperistaltic
segment lessens.
evidence:
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In total, 72 PM were identified in this series. At the end of the follow-up period, 38 PM (52.8%) had resolved, in 18 PM (25%) ureteral dilatation persisted and 16 PM (22.2%) required a surgical procedure."
explanation: >-
Quantifies the spontaneous-resolution, persistence, and eventual
surgical-requirement rates in long-term follow-up of primary
megaureter.
- phase: Obstructed and combined forms — persistent or progressive dilation with risk of surgical need
age_range: Infancy through childhood
notes: >-
A minority of cases, concentrated in the obstructed and combined forms,
show progressive hydroureteronephrosis or declining differential renal
function and require surgical correction rather than resolving
spontaneously.
evidence:
- reference: PMID:22397575
reference_title: "Long-term follow-up of neonatally diagnosed primary megaureter: rate and predictors of spontaneous resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Poor drainage on (99m)Tc-DTPA scan, grade IV-V hydronephrosis and ureteric diameter more than 15.0 mm were statistically significant and independent predictive factors for surgery."
explanation: >-
Identifies high-grade hydronephrosis, poor drainage, and larger
ureteral diameter as predictors of progression to surgery rather than
spontaneous resolution.
diagnosis:
- name: Renal and Bladder Ultrasonography
description: >
Prenatal or postnatal ultrasound is the first-line imaging study; it
establishes ureteral and collecting-system dilation and provides the
measured ureteric diameter (>7 mm is considered abnormal) used to define
a megaureter in the first place.
diagnosis_term:
preferred_term: renal ultrasound
term:
id: NCIT:C159885
label: Renal Ultrasound
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The BAPU defined a ureteric diameter over 7 mm as abnormal."
explanation: >-
Establishes the ultrasound-measured diameter threshold used to define
pathological ureteral dilation.
- name: Voiding Cystourethrography to Exclude Reflux and Bladder Outlet Obstruction
description: >
A micturating cystourethrogram (MCUG/VCUG) is performed to exclude
vesicoureteral reflux and bladder outlet obstruction (e.g., posterior
urethral valves). This step is what makes the diagnosis "primary" rather
than secondary: a positive reflux finding does not exclude the disease,
but instead reclassifies the case into the refluxing or combined form,
while a mechanical bladder-outlet lesion reclassifies it as secondary
megaureter, out of scope for this entry.
diagnosis_term:
preferred_term: cystography
term:
id: NCIT:C38049
label: Cystography
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "be investigated with an ultrasound scan and micturating cystourethrogram, followed by a diuretic renogram once VUR and bladder outlet obstruction had been excluded"
explanation: >-
A national consensus statement specifies the diagnostic sequence used
to exclude vesicoureteral reflux and bladder outlet obstruction before
a case is confirmed as (or subtyped within) primary megaureter.
- name: Diuretic Renography for Differential Renal Function and Drainage
description: >
A diuretic (MAG-3) renogram is obtained once reflux and bladder outlet
obstruction have been excluded, to quantify differential renal function
(DRF) and drainage; a DRF below 40%, or a drop in differential function
on serial studies, is an indication for surgical intervention rather than
continued observation.
diagnosis_term:
preferred_term: renography
term:
id: NCIT:C38086
label: Renography
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a DRF below 40% associated with massive or progressive hydronephrosis, or a drop in differential function on serial renograms"
explanation: >-
Establishes the diuretic-renogram-derived differential-renal-function
threshold used to decide between continued observation and surgery.
treatments:
- name: Surveillance and Expectant Management
description: >
Conservative management with serial ultrasound (and, when indicated,
functional renal scintigraphy) to monitor for spontaneous resolution or
stabilization of ureteral dilation, the standard approach for the
non-obstructed, non-refluxing form, which most often improves or resolves
without intervention as the child grows.
action_category: MONITORING
treatment_term:
preferred_term: supportive care
term:
id: NCIT:C15747
label: Supportive Care
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Initial management of primary megaureters is conservative."
explanation: >-
A national consensus statement establishes conservative management as
the standard initial approach.
- reference: PMID:38441661
reference_title: "Primary non-refluxing megaureter: Natural history, follow-up and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most often PMU remains asymptomatic with spontaneous resolution allowing for non-operative management."
explanation: >-
Supports non-operative management as appropriate given the frequency of
spontaneous resolution, particularly in the non-obstructed
non-refluxing form.
- name: Continuous Antibiotic Prophylaxis
description: >
Low-dose prophylactic antibiotics to reduce the risk of febrile urinary
tract infection while reflux or high-grade dilation is present or being
monitored.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The recommendation was for newborns with prenatally diagnosed hydroureteronephrosis to receive antibiotic prophylaxis"
explanation: >-
A national consensus statement recommends antibiotic prophylaxis in
newborns with prenatally diagnosed hydroureteronephrosis pending
diagnostic work-up.
- name: Ureteral Reimplantation with Tailoring
description: >
Surgical excision of the aperistaltic segment with tapering or folding
(tailoring) of the dilated distal ureter and reimplantation into the
bladder using an antireflux technique, indicated for progressive
obstruction, high-grade reflux, deteriorating renal function, or
breakthrough infection despite prophylaxis — most often required in the
obstructed and combined forms.
treatment_term:
preferred_term: Surgical Procedure
term:
id: NCIT:C15329
label: Surgical Procedure
target_mechanisms:
- target: Aperistaltic Juxtavesical Ureteric Segment
treatment_effect: BYPASSES
description: >-
The diseased, aperistaltic segment is excised outright and replaced
with a tapered, reimplanted ureter using an antireflux tunnel — the
defective segment is removed rather than restored to normal
peristaltic function.
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The BAPU recommended a ureteral reimplantation in patients over 1 year of age but recognized that the procedure may be challenging in infancy."
explanation: >-
A national consensus statement recommends ureteral reimplantation,
which excises the aperistaltic segment, as the definitive procedure
for progressive disease.
evidence:
- reference: PMID:24206785
reference_title: "British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The BAPU recommended a ureteral reimplantation in patients over 1 year of age but recognized that the procedure may be challenging in infancy."
explanation: >-
A national consensus statement recommends ureteral reimplantation as
the definitive surgical procedure for progressive disease.
- reference: PMID:11387761
reference_title: "Megaureter: classification, pathophysiology, and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Operative intervention is indicated only in these cases: significant impairment to urine flow; worsening renal function during the observation time; recurrent UTI in spite of adequate antibiotic prophylaxis."
explanation: >-
Establishes the accepted indications for surgical correction of
primary megaureter.
- name: Endoscopic High-Pressure Balloon Dilation
description: >
Endoscopic dilation of the aperistaltic ureterovesical junction segment
with a high-pressure balloon catheter, followed by temporary double-J
stenting, increasingly used as a less invasive alternative to open
ureteral reimplantation for the obstructed form.
therapeutic_modality: DEVICE
treatment_term:
preferred_term: Balloon Dilation
term:
id: NCIT:C113728
label: Balloon Dilation
target_mechanisms:
- target: Aperistaltic Juxtavesical Ureteric Segment
treatment_effect: MODULATES
description: >-
Mechanical dilation of the aperistaltic segment widens its lumen so
that urine can pass by relatively passive flow despite the segment's
persistent failure to generate an active peristaltic wave; the
segment's contractile deficit itself is not corrected.
evidence:
- reference: PMID:30345263
reference_title: "Long-Term Outcomes in Primary Obstructive Megaureter Treated by Endoscopic Balloon Dilation. Experience After 100 Cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "EBD of the vesicoureteral junction was performed with semicompliant high-pressure balloon catheters (2.7FG) with minimum balloon diameter of 5 mm, followed by temporary Double-J stent placement."
explanation: >-
Describes the endoscopic balloon dilation procedure as mechanically
widening the ureterovesical junction segment rather than restoring
its contractile activity.
evidence:
- reference: PMID:30345263
reference_title: "Long-Term Outcomes in Primary Obstructive Megaureter Treated by Endoscopic Balloon Dilation. Experience After 100 Cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Endoscopic approach of POM had a long-term success rate of 87.3%, with a mean follow-up of 6.4 ± 3.8 years."
explanation: >-
A large single-center series reports a high long-term success rate for
endoscopic balloon dilation in obstructed primary megaureter.
- reference: PMID:38954357
reference_title: "Advancements in Surgical Management of Megaureters."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Endoscopic balloon dilation has been on the rise as a major treatment option for obstructive megaureter, while refluxing megaureters can also be treated by laparoscopic and robotic techniques, whether extravesically or transvesicoscopically."
explanation: >-
A 2024 review confirms endoscopic balloon dilation as an increasingly
used surgical option specifically for the obstructed form.
- name: Temporizing Urinary Diversion
description: >
Cutaneous ureterostomy or nephrostomy drainage used as a temporizing
measure in severe neonatal or infantile disease (e.g., with sepsis, poor
renal function, or a very small infant) prior to definitive
reimplantation.
treatment_term:
preferred_term: Surgical Procedure
term:
id: NCIT:C15329
label: Surgical Procedure
evidence:
- reference: PMID:31968361
reference_title: "[Primary megaureter in the newborn period: making the case for a temporary splint-free cutaneous ureterostomy]."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "in a first step, we place a temporary splint-free ureterocutaneostomy for early disobstruction"
explanation: >-
Supports a temporary cutaneous ureterostomy as a first-stage
temporizing measure in severely dilated neonatal megaureter, prior to
definitive corrective surgery.
clinical_trials:
- name: NCT05639283
phase: NOT_APPLICABLE
status: COMPLETED
description: >-
A completed French retrospective observational study (POMME registry,
120 patients) characterizing current management and outcomes of primary
obstructive megaureter across an interregional care area.
target_phenotypes:
- preferred_term: Congenital megaureter
term:
id: HP:0008676
label: Congenital megaureter
- preferred_term: Hydronephrosis
term:
id: HP:0000126
label: Hydronephrosis
evidence:
- reference: clinicaltrials:NCT05639283
reference_title: "Primary Obstructive Megaureter Management in Eastern Interregional Area : Current Status and Perspectives"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The obstruction is linked to aperistalsis and hypertrophy of the circular muscle bundles and increased collagen 1 level."
explanation: >-
The trial's own summary independently states the aperistalsis, circular
muscle hypertrophy, and increased collagen mechanism modeled by this
entry's core pathophysiology node.
discussions:
- discussion_id: megaureter_no_validated_animal_model
prompt: >-
Does a validated animal model of isolated (non-syndromic) primary
megaureter exist that reproduces the aperistaltic-segment mechanism, so
the developmental origin of the abnormal circular:longitudinal muscle
ratio and collagen deposition can be tested experimentally?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- animal_models#
- pathophysiology#Aperistaltic Juxtavesical Ureteric Segment
rationale: >-
No mouse, rat, zebrafish, or organoid model of isolated primary
obstructive megaureter is established in the literature reviewed for
this entry, so the developmental origin of the aperistaltic segment
(a smooth-muscle differentiation or maturation defect versus a
structural anomaly of the ureteric bud) has not been tested causally
in a model system. Resolving this would let the "delayed smooth-muscle
maturation" hypothesis for spontaneous resolution be tested directly.
proposed_experiments:
- experiment_id: megaureter_mouse_smooth_muscle_perturbation
name: Conditional ureteric smooth-muscle differentiation perturbation in mouse
description: >-
A conditional or hypomorphic perturbation of ureteric smooth-muscle
differentiation genes in mouse, timed to the equivalent of the
third-trimester ureteric bud/metanephric mesenchyme interaction window,
scored for a juxtavesical aperistaltic segment and collagen deposition
by whole-mount contractility imaging and histology.
- discussion_id: megaureter_no_clingen_gene_disease_relationship
prompt: >-
Is there a single-gene or oligogenic cause of isolated primary
megaureter distinct from the broader CAKUT gene set (PAX2, TBX18, SIX2,
BMP4, NRIP1, and others), which explain CAKUT generally but have not
been shown to cause isolated megaureter specifically?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- genetic#
rationale: >-
No ClinGen-level gene-disease validity relationship, recurrent
pathogenic variant, inheritance pattern, or carrier frequency has been
established for isolated congenital primary megaureter. This is why
`genetic:` is deliberately absent from this entry: the broader CAKUT
gene set is well documented for CAKUT as a whole, but attributing it to
isolated primary megaureter specifically would be unsupported
extrapolation.
evidence:
- reference: PMID:39076761
reference_title: "Congenital anomalies of the kidney and urinary tract."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Defects in specific genes such as PAX2, TBX18, NRIP1, REX, SIX2, BMP4, and chromosome 17 cause CAKUT."
explanation: >-
Establishes the genes documented for CAKUT as a whole; the entry does
not address primary megaureter specifically, which is the gap this
discussion records — the general CAKUT gene set should not be
mechanically re-attributed to this specific, largely idiopathic
lesion.
- discussion_id: megaureter_no_replicated_omics_signature
prompt: >-
Would a transcriptomic, proteomic, or single-cell profile of the
aperistaltic segment versus the adjacent normally peristaltic ureter
identify the molecular drivers of the abnormal circular:longitudinal
muscle ratio and collagen deposition?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Aperistaltic Juxtavesical Ureteric Segment
rationale: >-
No replicated transcriptomic, proteomic, single-cell, or spatial
profiling study of the aperistaltic segment has been identified in the
literature reviewed for this entry. TGF-beta signaling and collagen
remodeling have been proposed as candidate pathways, but no molecular
profile has been generated to test them directly against the adjacent,
normally peristaltic ureter from the same patients.
proposed_experiments:
- experiment_id: megaureter_paired_segment_transcriptomics
name: Paired transcriptomic profiling of aperistaltic versus dilated ureteric segments
description: >-
Paired single-cell or bulk RNA-seq of the excised aperistaltic segment
and the adjacent dilated (normally muscularized) ureter obtained at the
same reimplantation surgery, contrasting smooth-muscle differentiation,
extracellular-matrix, and TGF-beta pathway gene expression between the
two regions.
Congenital primary megaureter is a congenital anomaly of the kidney and urinary tract (CAKUT) in which the ureter is abnormally enlarged—generally >7–8 mm in a child—without an acquired cause. “Megaureter” is an imaging description, not a complete etiologic diagnosis. Cases must be classified by the presence or absence of vesicoureteral reflux (VUR) and obstruction. The best-characterized disease subtype is primary obstructive megaureter (POM), also called primary non-refluxing obstructive megaureter, caused by a short adynamic or aperistaltic distal ureteral segment at the ureterovesical junction (UVJ). (boswell2024advancementsinsurgical pages 1-2, aiello2022efficacyandsafety pages 1-2)
Most prenatally detected POMs are initially observed because approximately 70–80% improve or resolve without surgery. Intervention is reserved for febrile/recurrent urinary infection, pain or stones, progressive hydroureteronephrosis, renal-parenchymal thinning, or declining differential renal function. The principal recent development is increasing use of endoscopic high-pressure balloon dilation; however, the evidence remains dominated by retrospective, single-center series rather than randomized trials. (ortiz2018longtermoutcomesin pages 1-2, boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 2-4, aiello2022efficacyandsafety pages 1-2)
The following table provides a compact ontology-ready summary; suggested ontology terms should be verified against the current releases before database ingestion.
| Domain | Knowledge-base statement | Quantitative evidence | Suggested ontology terms/IDs | Evidence level or caveat |
|---|---|---|---|---|
| Definition / classification | Congenital primary megaureter is a pediatric imaging-defined ureteral dilatation, usually >7–8 mm, that must be etiologically classified; the key primary subtype for this entry is primary obstructive/non-refluxing megaureter (POM), i.e., distal ureterovesical junction obstruction without vesicoureteral reflux. | Diameter threshold: >7–8 mm; classified by reflux present/absent and obstruction present/absent. | Candidate terms for curator verification: MONDO primary megaureter/congenital megaureter; MeSH megaureter; UBERON ureter, ureterovesical junction; HPO Hydroureter, Hydronephrosis | Strong review-level synthesis plus primary series; nomenclature varies across sources (primary obstructive, primary non-refluxing, congenital obstructive megaureter). (boswell2024advancementsinsurgical pages 1-2, aiello2022efficacyandsafety pages 1-2) |
| Data provenance | Most disease information is aggregated from disease-level reviews, retrospective pediatric cohorts, and registry studies rather than EHR-derived large population datasets. | No unified disease registry prevalence estimate identified. | Evidence model tags: human clinical; retrospective cohort; review; registry | Important for KB curation because many statements are from specialty-center series, not population-wide surveillance. (ortiz2018longtermoutcomesin pages 1-2, boswell2024advancementsinsurgical pages 1-2, NCT05639283 chunk 1) |
| Core phenotype | Typical phenotype is hydroureteronephrosis detected antenatally or in infancy/early childhood; diagnosis often follows prenatal ultrasound showing urinary tract dilatation. | CAKUT overall detectable on fetal ultrasonography; POM accessible to antenatal screening from second trimester; primary megaureter cited as 5–10% of prenatal hydronephrosis cases in one review/case-based synthesis. | HPO candidate terms: Antenatal hydronephrosis; Hydroureter; Hydronephrosis; Abnormal urinary system imaging finding | Direct disease-specific prenatal detection supported; 5–10% figure comes from later review/case literature and should be curator-verified before hard-coding. (NCT05639283 chunk 1, shrateh2025bilateralprimarynonrefluxing pages 2-5) |
| Principal clinical phenotypes | Common manifestations include urinary tract infection, progressive hydronephrosis/hydroureter, flank/loin pain, hematuria, nephrolithiasis, and loss of renal function in a subset; many infants remain asymptomatic under surveillance. | In one 79-POM surgical cohort, indications combined worsening hydroureteronephrosis with UTI, parenchymal thinning, and/or impaired differential renal function; in a small 11-case mixed megaureter series, febrile UTI occurred in 63.64% and lower back pain in 45.45%. | HPO candidate terms: Urinary tract infection; Flank pain; Hematuria; Nephrolithiasis; Decreased renal function; Renal parenchymal thinning | Symptom frequencies are highly cohort-dependent and enriched for referred/surgical patients. (ortiz2018longtermoutcomesin pages 1-2, morsoUnknownyearsupervidedbypr. pages 90-96, cayon2024comparativestudyof pages 1-2) |
| Anatomy affected | Primary organs: ureter and kidney collecting system; the lesion localizes to the distal/terminal ureter at the ureterovesical junction, with secondary impact on renal pelvis/calyces and renal parenchyma. | Distal obstructive/adynamic segment reported as short; one source notes 0.5–4 cm aperistaltic segment. | UBERON candidate terms: ureter; distal ureter; ureterovesical junction; renal pelvis; kidney; urinary system | Disease-specific localization is consistent across reviews and cohorts. (isac2025predictivefactorsfor pages 1-2, boswell2024advancementsinsurgical pages 1-2, NCT05639283 chunk 1) |
| Tissue / cell level | Pathology centers on distal ureteral smooth-muscle and extracellular-matrix abnormality, with functional aperistalsis/adynamia. | Histologic themes: focal muscle-fiber deficiency, proximal muscular hypertrophy, abnormal circular-fiber predominance, collagen infiltration/fibrosis. | CL candidate terms: smooth muscle cell; fibroblast; urothelial cell. GO candidate terms: smooth muscle contraction; extracellular matrix organization; collagen fibril organization; peristalsis | Mechanistic evidence is mainly histopathology and review synthesis, not modern single-cell data. (isac2025predictivefactorsfor pages 1-2, morsoUnknownyearsupervidedbypr. pages 29-32, NCT05639283 chunk 1, aiello2022efficacyandsafety pages 1-2) |
| Mechanism / causal chain | Proposed chain: congenital distal ureteral smooth-muscle differentiation defect → adynamic/aperistaltic UVJ segment → functional urinary outflow obstruction → upstream hydroureteronephrosis/tortuosity and stasis → infection, renal parenchymal thinning/scarring, and possible renal function decline. Spontaneous improvement likely reflects maturation of distal ureteral function over time. | Spontaneous resolution estimated around 72–80% in observational/review literature; maturation may continue for the first years of life. | GO candidate terms: smooth muscle cell differentiation; ureteral peristalsis; response to mechanical stress; fibrosis; kidney development | Disease-specific mechanism is plausible and repeatedly cited, but molecular drivers remain insufficiently defined. (boswell2024advancementsinsurgical pages 1-2, aiello2022efficacyandsafety pages 1-2, isac2025predictivefactorsfor pages 1-2, NCT05639283 chunk 1) |
| Laterality / demographics | Male predominance is typical; unilateral disease is more common, but bilateral involvement is well recognized. | Trial synopsis: affects four times more boys than girls; bilateral in 25%; contralateral renal dysplasia in 15%. Older summary: bilateral in ~25%, contralateral absence/dysplasia 10–15%. | HPO candidate terms: Bilateral hydroureter; Unilateral hydroureter; Renal dysplasia | These proportions derive from specialty literature and registry synopsis rather than population registries. (NCT05639283 chunk 1, morsoUnknownyearsupervidedbypr. pages 29-32) |
| Natural history | Most primary non-refluxing/obstructive megaureters improve or resolve without surgery, usually with gradual proximal-to-distal reduction in dilatation. A minority progress and require intervention. | Historic prenatal cohort: spontaneous resolution in 72% at mean >2 years; prospective data summarized in 2024 review: ureter <10 mm had 76% resolution over median 5 years vs 17% for ≥10 mm over median 9 years; 2025 conservative cohort: 57% spontaneous resolution at median 45.75 months. | HPO candidate terms: Spontaneous resolution; Persistent hydroureter; Progressive hydronephrosis | Natural-history estimates differ by inclusion criteria and era; 2025 cohort is newer but small and outside requested 2023–2024 priority window. (boswell2024advancementsinsurgical pages 1-2, isac2025predictivefactorsfor pages 1-2, isac2025predictivefactorsfor pages 10-12) |
| Prognostic / resolution predictors | Worse spontaneous-resolution likelihood is associated with greater hydronephrosis severity and larger ureteral diameter. | Predictors cited: SFU grade 3–4 hydronephrosis and ureter diameter >13 mm; <10 mm vs ≥10 mm ureter threshold associated with 76% vs 17% resolution in one prospective study; 2025 cohort found hydronephrosis grade significant (p=0.046). | HPO candidate terms: Severe hydronephrosis; Enlarged ureter | Good candidate features for prognostic annotations; external validation remains limited. (boswell2024advancementsinsurgical pages 1-2, isac2025predictivefactorsfor pages 10-12) |
| Diagnostics: ultrasound | Serial renal/bladder ultrasound is the backbone of diagnosis and follow-up, measuring pelvis/calyces/distal ureter diameter and renal parenchyma. | Example surveillance in one cohort: at birth, 1 month, then every 3 months during conservative follow-up; after EBD, US at 3, 6, 12, and 18 months then annually. | LOINC/RadLex candidate terms: renal/bladder ultrasound; UBERON kidney/ureter/bladder; HPO renal pelvis dilatation | Strong real-world use; exact protocols vary by center. (ortiz2018longtermoutcomesin pages 1-2, ortiz2018longtermoutcomesin pages 4-5, boswell2024advancementsinsurgical pages 1-2) |
| Diagnostics: VCUG | Voiding cystourethrography is used early to exclude reflux and secondary causes; absence of reflux plus significant ureteral dilation supports POM. | Postoperative VCUG in one EBD cohort was reserved for UTI or persistent dilatation without renographic obstruction. | Candidate terms: VCUG; HPO Vesicoureteral reflux (for exclusion); UBERON bladder/urethra | Essential differential test; reflux does not absolutely exclude obstructive component in mixed/ORM cases. (boswell2024advancementsinsurgical pages 1-2, ortiz2018longtermoutcomesin pages 4-5) |
| Diagnostics: MAG-3 renography | Diuretic renography helps assess obstruction and split renal function, but delayed washout alone should not automatically trigger surgery in an asymptomatic stable child. | Obstruction threshold in one cohort: T1/2 >20 min after furosemide; BAPU criteria summarized in 2024 review: initial DRF <40% or DRF drop ≥5% on serial scans support surgery. | Candidate terms: MAG-3 renogram; Differential renal function; Obstructive washout pattern | Important caveat: washout curves are error-prone in tortuous dilated ureters and practice varies because of radiation/cost/catheterization burden. (ortiz2018longtermoutcomesin pages 1-2, boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 2-4) |
| Differential diagnosis | Secondary megaureter causes must be ruled out, including posterior urethral valves, neurogenic bladder, and other bladder outlet/voiding disorders; obstructed refluxing megaureter also exists. | No single quantitative differential metric identified. | Candidate terms: posterior urethral valves; neurogenic bladder; secondary megaureter; obstructed refluxing megaureter | Diagnosis is etiologic exclusion plus imaging pattern recognition. (boswell2024advancementsinsurgical pages 1-2) |
| Conservative management | Observation is first-line for most cases; some centers use low-dose antibiotic prophylaxis during infancy/surveillance, but broader hydronephrosis literature indicates prophylaxis benefit remains controversial and should be individualized. | One POM cohort used low-dose antibiotic prophylaxis during conservative surveillance and usually stopped it by 6 months after adequate postoperative drainage; broader 2024 hydronephrosis review: CAP benefit remains controversial. | NCIT candidate interventions: Active surveillance; Antibiotic prophylaxis | Disease-specific randomized evidence for prophylaxis is lacking. (ortiz2018longtermoutcomesin pages 1-2, ortiz2018longtermoutcomesin pages 4-5) |
| Operative criteria | Intervention is generally reserved for worsening hydroureteronephrosis plus clinical or functional deterioration: febrile/recurrent UTI, pain, stones, hematuria, declining DRF, marked progressive dilation, or parenchymal thinning. | In 79 operated POMs: worsening UHN+UTI 38%; worsening UHN+parenchymal thinning 36.7%; worsening UHN+DRF impairment 17.7%; all three 7.6%. | HPO candidate terms: Progressive hydronephrosis; Recurrent urinary tract infections; Renal function decline. NCIT candidate: Surgical indication | These frequencies reflect reasons for surgery among selected operated patients, not disease prevalence. (ortiz2018longtermoutcomesin pages 1-2, aiello2022efficacyandsafety pages 1-2, cayon2024comparativestudyof pages 1-2) |
| Standard surgery | Traditional gold standard is distal ureteral reimplantation/ureteroneocystostomy, with or without tapering/tailoring/remodeling. | Reported success for open reimplantation ± tapering: ~90–95% or 90–96%. | NCIT candidate interventions: Ureteral reimplantation; Ureteroneocystostomy; Ureteroplasty/tapering | High success but greater technical complexity and morbidity in infants with very dilated ureters and small bladders. (ortiz2018longtermoutcomesin pages 4-5, aiello2022efficacyandsafety pages 1-2, boswell2024advancementsinsurgical pages 2-4) |
| Endoscopic balloon dilation (EBD/HPBD) | High-pressure balloon dilation of the UVJ has become a major minimally invasive treatment option for POM and can be definitive in many infants/children. | Systematic review: success 69–100%, may avoid surgery in up to 77%, complications 0–50% mostly infectious or stent-related; 100-case long-term series: success 87.3%, secondary VUR 21.5%, re-stenosis 12.2%, reimplantation needed in 12.7%, mean follow-up 6.4±3.8 years. | NCIT candidate interventions: Endoscopic balloon dilation; Ureteral stent placement; Endoscopic injection for VUR | Evidence is largely retrospective single-center and heterogeneous; still probably the most important recent real-world shift. (aiello2022efficacyandsafety pages 1-2, ortiz2018longtermoutcomesin pages 1-2, ortiz2018longtermoutcomesin pages 7-8, boswell2024advancementsinsurgical pages 2-4) |
| Recent 2024 procedural development | Some centers now perform POM balloon dilation under cystoscopic control alone, omitting fluoroscopy to reduce ionizing radiation. | Comparative 2024 study (23 patients): hospital stay 1 vs 2 days (CS vs RX, p=0.009); OR time 30 vs 78 min (p=0.001); long-term success 100% vs 71%. | NCIT candidate interventions: Radiation-sparing endoscopic balloon dilation; Cystoscopy | Small retrospective study; promising but not definitive. (cayon2024comparativestudyof pages 1-2) |
| Stents / temporizing drainage | Internal stents or cutaneous ureterostomy may be used as temporizing strategies, especially in infants or infection, but stents have notable complication burdens. | Review summary: older stenting literature left about half avoiding surgery after 3–6 months; more recent 35-ureter study showed only 25% avoided subsequent surgery and ~40% had stent-period issues. | NCIT candidate interventions: Ureteral stent placement; Cutaneous ureterostomy; Nephrostomy | Mostly historical/bridging role; not a definitive solution for many patients. (boswell2024advancementsinsurgical pages 2-4) |
| Robotic / laparoscopic surgery | Minimally invasive reconstructive surgery is increasingly reported for selected centers and surgeons, including robotic Lich-Gregoir and other extravesical/transvesicoscopic techniques. | Robotic Lich-Gregoir series: 18 patients, 39% tapered, all improved hydronephrosis over median 2 years; multicenter comparison of 47 laparoscopic vs 48 robotic cases: 94–97% success, 2–4% high-grade complications; single-center robotic vs open: 91–92% success, 8–9% complication rates. | NCIT candidate interventions: Robotic ureteral reimplantation; Laparoscopic ureteral reimplantation | Highly center-dependent learning curve; broad uptake remains limited. (boswell2024advancementsinsurgical pages 4-5) |
| Outcomes / prognosis | Renal drainage and imaging usually improve after successful intervention; long-term prognosis is generally good with preserved renal function when monitored and treated appropriately, but untreated progressive cases risk scarring/function loss. | After EBD: MAG-3 drainage improved from T1/2 >50 min baseline to 9.8±4.5 min post-op (p<0.001); mean DRF 44.4% to 46.2% (p<0.05), with no later deterioration in that series. | HPO candidate terms: Renal scarring; Chronic kidney disease; Preserved renal function | Mortality/life expectancy statistics specific to this disease were not identified. (ortiz2018longtermoutcomesin pages 4-5, NCT05639283 chunk 1) |
| Epidemiology | Primary megaureter is an uncommon congenital urinary tract malformation within CAKUT; disease-specific population prevalence/incidence remains poorly defined. | CAKUT overall affects >1% of live births; clinical-trial synopsis calls congenital obstructive megaureter the second most common cause of hydronephrosis; one older summary cites megaureter as 23% of obstructive uropathy cases. | Candidate terms: CAKUT; congenital urinary tract obstruction | Use caution: most epidemiology is extrapolated from CAKUT/hydronephrosis or tertiary-center series, not dedicated population studies. (mahmoud2024congenitalanomaliesof pages 1-2, NCT05639283 chunk 1, morsoUnknownyearsupervidedbypr. pages 29-32) |
| Genetics / inheritance | No validated disease-specific monogenic cause, recurrent pathogenic variant set, inheritance pattern, penetrance estimate, or ClinGen-style gene-disease curation was identified for congenital primary megaureter itself. | None established from retrieved disease-specific evidence. | Candidate annotation: genetics unknown/heterogeneous; broader CAKUT genes for separate curation only (e.g., PAX2, TBX18, SIX2, BMP4 in CAKUT context) | Important negative finding: do not over-attribute broad CAKUT genes to primary megaureter without direct evidence. (mahmoud2024congenitalanomaliesof pages 1-2) |
| Environmental / protective factors | No disease-specific environmental risk factor, protective factor, or gene-environment interaction was identified for primary megaureter. Broader CAKUT literature implicates maternal diabetes, obesity, malnutrition, alcohol, and nephrotoxic medications in urinary tract maldevelopment generally. | None disease-specific. | Candidate annotation: environmental evidence unavailable for disease-specific entry | Keep separate from generic CAKUT etiologic risk factors. (mahmoud2024congenitalanomaliesof pages 1-2) |
| Molecular profiling / epigenetics | No validated disease-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial, or epigenetic biomarker set was identified in the retrieved evidence. | Not available. | Candidate annotation: no omics signature established | Useful KB gap statement. (isac2025predictivefactorsfor pages 1-2, mahmoud2024congenitalanomaliesof pages 1-2) |
| Other species / model organisms | No validated natural veterinary disease model or dedicated model-organism system for primary congenital megaureter was identified in retrieved evidence. | Not available. | Candidate annotation: model organism unavailable/not established | Absence of evidence from targeted search; curator may revisit specialist databases separately. (isac2025predictivefactorsfor pages 1-2) |
| Clinical trials / current research | Interventional trial activity is sparse; one relevant completed observational registry-style study is POMME. Current research focus is on optimizing selection for observation vs minimally invasive intervention and comparing endoscopic with reconstructive approaches. | POMME / NCT05639283: completed retrospective observational study, enrollment 120, University Hospital Strasbourg; no relevant gene/cell/RNA/drug trials found. | Trial IDs: NCT05639283; candidate evidence tags: observational registry, real-world study | Supports statement that management advances are procedural rather than molecular/targeted. (NCT05639283 chunk 1, boswell2024advancementsinsurgical pages 1-2) |
Table: This table summarizes ontology-ready, disease-specific facts for congenital primary megaureter, emphasizing definition, pathophysiology, natural history, diagnostics, treatment, and key evidence gaps. It is designed to help curate a structured knowledge-base entry while clearly separating direct evidence from broader CAKUT context.
A megaureter is a ureter measuring more than approximately 7–8 mm, usually identified by pediatric ultrasonography. King/Smith-style classification separates it into: (1) refluxing, non-obstructed; (2) obstructed, non-refluxing—POM; (3) refluxing and obstructed; and (4) neither refluxing nor obstructed. Each may be primary or secondary. Primary disease originates in the ureter/UVJ; secondary megaureter results from such conditions as posterior urethral valves, neurogenic bladder, or other high-pressure bladder/outlet disorders. (boswell2024advancementsinsurgical pages 1-2, aiello2022efficacyandsafety pages 1-2)
The 2024 review’s exact abstract wording is: “Megaureter management first relies on determining the underlying cause, whether by obstruction, reflux, or a combination.” This is clinically important because treatment of reflux alone can miss a coexisting obstructive component. (boswell2024advancementsinsurgical pages 1-2)
Common names include congenital megaureter, primary megaureter, primary obstructive megaureter, primary non-refluxing megaureter, primary non-refluxing obstructive megaureter, congenital obstructive megaureter, and functional UVJ obstruction. “Primary non-refluxing megaureter” is sometimes used as a broader observational cohort label and may include obstructed and non-obstructed units.
No confidently disease-specific OMIM, Orphanet, or MONDO identifier was established in the retrieved authoritative material. A current ontology lookup should therefore be performed before assigning a code; do not substitute a generic hydronephrosis or CAKUT identifier. The relevant ClinicalTrials.gov record maps the condition to MeSH Hydronephrosis, D006869, but this is broader than POM. ICD coding is likewise generally under congenital obstructive defects of the renal pelvis/ureter or other congenital urinary malformations rather than a uniquely validated POM code. (NCT05639283 chunk 1)
The evidence is aggregated at disease level from reviews, retrospective pediatric-urology cohorts, imaging follow-up studies, and a small number of prospective observational cohorts. It is not principally based on individual longitudinal EHR records or a population-wide disease registry. This limits precise prevalence and phenotype-frequency estimates.
POM is attributed to abnormal development or maturation of the terminal ureter, producing an adynamic/aperistaltic segment and functional obstruction at the UVJ. Histologic descriptions include focal smooth-muscle deficiency, disproportionate circular-muscle bundles, proximal muscular hypertrophy, collagen infiltration, and increased collagen I/III. Delayed smooth-muscle differentiation may explain why many cases resolve during infancy or early childhood. (isac2025predictivefactorsfor pages 1-2, morsoUnknownyearsupervidedbypr. pages 29-32, NCT05639283 chunk 1, aiello2022efficacyandsafety pages 1-2)
No validated single causal gene, recurrent pathogenic variant, inheritance pattern, penetrance estimate, founder allele, or carrier frequency was identified specifically for isolated congenital primary megaureter. Consequently, broad CAKUT genes must not automatically be annotated as causal for this phenotype.
A 2024 CAKUT review lists genes including PAX2, TBX18, SIX2, BMP4, and NRIP1 and states that monogenic variants may explain up to 20% of CAKUT overall. That evidence applies to the heterogeneous CAKUT spectrum, not specifically to isolated POM. Genetic testing is more defensible when megaureter is bilateral, familial, syndromic, associated with renal dysplasia/agenesis, or accompanied by other congenital anomalies. (mahmoud2024congenitalanomaliesof pages 1-2)
No toxin, infection, diet, smoking exposure, occupational factor, or lifestyle behavior has been demonstrated as a disease-specific cause of primary megaureter. Maternal diabetes, obesity, malnutrition, alcohol, and medications that disturb renal development have been discussed for CAKUT collectively, but disease-specific effect sizes for POM are unavailable. No established genetic or environmental protective factors or gene–environment interaction has been demonstrated. (mahmoud2024congenitalanomaliesof pages 1-2)
The typical onset is prenatal, neonatal, or early childhood. Severity ranges from asymptomatic ureteral dilation to progressive obstructive nephropathy.
In a selected cohort of 79 operated POM units, indications were worsening hydroureteronephrosis with UTI in 38%, parenchymal thinning in 36.7%, impaired differential function in 17.7%, and the combination of UTI plus impaired function in 7.6%. These are surgical-cohort frequencies, not prevalence among all affected children. (ortiz2018longtermoutcomesin pages 1-2)
Disease-specific quality-of-life instruments or EQ-5D/SF-36 data were not identified. Most asymptomatic children have little day-to-day impairment but undergo prolonged imaging and infection surveillance; recurrent pyelonephritis, pain, hospitalization, and surgery can materially affect child and family well-being.
There is presently insufficient evidence to populate a disease-specific causal-gene or pathogenic-variant table. No robust ClinGen-level gene–disease relationship, pathogenic variant spectrum, allele frequency, somatic event, modifier gene, chromosomal abnormality, or pharmacogenomic association was identified.
Accordingly, routine isolated-POM management is not genotype directed. If genomic testing is clinically indicated because of syndromic or complex CAKUT, chromosomal microarray followed by a CAKUT panel or exome/genome sequencing may be considered under clinical-genetics guidance. Results should be interpreted against the patient’s complete renal and extrarenal phenotype; a variant in a general kidney-development gene is not automatically explanatory for megaureter. Broad CAKUT evidence supports NGS as an adjunct in selected patients, but not as a replacement for functional urinary-tract imaging. (mahmoud2024congenitalanomaliesof pages 1-2)
No disease-specific DNA-methylation signature, histone alteration, chromatin abnormality, or validated epigenetic biomarker is known from the retrieved evidence.
There is no evidence that postnatal pollution, radiation, occupation, diet, exercise, alcohol, smoking, or infection creates congenital primary megaureter. The malformation is present during fetal urinary-tract development. General maternal CAKUT risks may be recorded as contextual—not POM-specific—evidence. No vaccine or antimicrobial prevention of the congenital lesion is applicable. (mahmoud2024congenitalanomaliesof pages 1-2)
The best-supported disease model is:
disturbed terminal-ureter smooth-muscle differentiation/maturation → short distal adynamic or aperistaltic segment → impaired antegrade urine transport at the UVJ → proximal ureteral dilation and tortuosity → renal-pelvic/calyceal dilation and urinary stasis → febrile UTI, pressure/mechanical injury, parenchymal thinning or scarring → loss of differential renal function in severe progressive cases. (isac2025predictivefactorsfor pages 1-2, NCT05639283 chunk 1, aiello2022efficacyandsafety pages 1-2)
Upstream processes are smooth-muscle differentiation, extracellular-matrix organization, and acquisition of coordinated peristalsis. Downstream processes are urinary stasis, infection/inflammation, mechanical distension, fibrosis/scarring, and obstructive nephropathy. The spontaneous-resolution phenotype supports a developmental-maturation mechanism rather than an invariably fixed anatomic stenosis.
Suggested GO annotations include smooth muscle cell differentiation, smooth muscle contraction, ureteral peristalsis, extracellular matrix organization, collagen fibril organization, response to mechanical stimulus, and fibrotic process. Candidate Cell Ontology terms include smooth muscle cell, fibroblast, and urothelial cell. These are biologically appropriate annotations but should be mapped to exact current GO/CL identifiers by an ontology curator.
No replicated disease-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, multi-omic, or CRISPR-screen signature was identified. TGF-β and collagen remodeling have been proposed in maturation/fibrosis, but there is not enough evidence to designate a clinically actionable molecular pathway or biomarker. (isac2025predictivefactorsfor pages 1-2)
The primary site is the distal ureter and UVJ; upstream structures include the remaining ureter, renal pelvis, calyces, renal parenchyma, and occasionally the contralateral urinary tract. Suggested UBERON concepts are ureter, distal ureter, ureterovesical junction, urinary bladder, renal pelvis, kidney, and urinary system.
The relevant tissues are ureteral smooth muscle, extracellular matrix/connective tissue, urothelium, and—secondarily—renal parenchyma. No disease-defining subcellular organelle abnormality is known. Disease is usually unilateral, but approximately 25% of cases are bilateral; one registry synopsis reports contralateral renal dysplasia in approximately 15%. Male predominance is marked, with the POMME record describing roughly four times as many boys as girls. (NCT05639283 chunk 1)
The lesion is congenital and can be detected by ultrasound from the second trimester. Many affected newborns remain asymptomatic. Resolution is generally gradual and may proceed from proximal to distal ureter as peristaltic function matures. (NCT05639283 chunk 1, boswell2024advancementsinsurgical pages 1-2)
Observational literature reports approximately 72–80% spontaneous improvement/resolution. A prospective study summarized in the 2024 review found 76% resolution over a median five years when ureteral diameter was <10 mm, versus 17% over a median nine years when diameter was ≥10 mm. Higher SFU hydronephrosis grade and ureteral diameter >13 mm predict a greater likelihood of meeting surgical criteria. (boswell2024advancementsinsurgical pages 1-2, aiello2022efficacyandsafety pages 1-2)
The critical intervention window is not a fixed age. It is defined by emerging febrile infection, progressive dilation or parenchymal thinning, and declining function. Stable asymptomatic dilation—even with delayed renographic washout—does not necessarily represent renal-damaging obstruction. Long-term surveillance is important because resolution may take years and late symptomatic presentation is possible.
Disease-specific population incidence and prevalence per 100,000 are not well established. Primary megaureter has been estimated to account for approximately 5–10% of prenatal hydronephrosis in secondary literature, but this estimate is not equivalent to population prevalence. CAKUT as a whole affects more than 1% of live births and accounts for a large fraction of childhood kidney failure; these broader figures should not be assigned directly to POM. (shrateh2025bilateralprimarynonrefluxing pages 2-5, mahmoud2024congenitalanomaliesof pages 1-2)
Available cohorts consistently indicate male predominance and predominantly unilateral disease, with bilaterality near 25%. No reliable ethnic, geographic, founder, consanguinity, anticipation, germline-mosaicism, or carrier-frequency pattern has been established. (NCT05639283 chunk 1)
The 2024 expert review cautions that delayed washout alone is not an appropriate operative trigger. More persuasive functional criteria are initial DRF <40% or a serial decline of at least 5%, considered together with symptoms and ultrasound progression. (boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 2-4)
One published protocol obtained ultrasound at birth, one month, and every three months during conservative surveillance. After balloon dilation, ultrasound was performed at 3, 6, 12, and 18 months and annually thereafter; MAG-3 scans were obtained at 6 and 18 months. Protocols differ among centers. (ortiz2018longtermoutcomesin pages 1-2, ortiz2018longtermoutcomesin pages 4-5)
Important exclusions are refluxing megaureter, mixed obstructed-refluxing megaureter, posterior urethral valves, neurogenic or high-pressure bladder, ureterocele/duplicated collecting system, ectopic ureter, UVJ calculus or acquired stricture, retroperitoneal compression, and severe bladder/bowel dysfunction. POM is therefore a clinicoradiologic and functional diagnosis rather than a diagnosis based solely on ureteral diameter.
No genetic, circulating, proteomic, metabolomic, epigenomic, or liquid-biopsy test diagnoses isolated POM. CMA, CAKUT panels, WES, or WGS are reserved for selected syndromic, familial, bilateral, or multisystem presentations. Karyotyping, FISH, mitochondrial testing, and repeat-expansion assays have no routine disease-specific role.
With observation and timely treatment where needed, prognosis and renal preservation are generally favorable. Disease-specific mortality and reduced life expectancy have not been demonstrated; five- or ten-year survival statistics are therefore not meaningful endpoints. Morbidity derives instead from recurrent pyelonephritis, renal scarring, pain/stones, repeated imaging, stent complications, surgery, and—in severe bilateral or solitary-kidney disease—renal failure. The POMME registry synopsis explicitly identifies repeated pyelonephritis, kidney scarring, and impaired kidney function as clinically relevant risks. (NCT05639283 chunk 1)
After successful endoscopic dilation in a 79-unit long-term cohort, MAG-3 drainage improved from T½ >50 minutes to 9.8±4.5 minutes, mean DRF increased from 44.4% to 46.2%, and no subsequent functional deterioration was observed. Pelvic diameter fell from 19.2 to 5.2 mm and ureteral diameter from 14.9 to 6.6 mm at long-term follow-up. These favorable results are from a selected treated cohort rather than comparative randomized evidence. (ortiz2018longtermoutcomesin pages 4-5)
Poorer prognostic features include high-grade hydronephrosis, large ureteral diameter, progressive parenchymal thinning, recurrent febrile UTI, DRF <40%, and a serial DRF decline ≥5%. No validated molecular prognostic biomarker exists. (boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 2-4)
Active surveillance is first-line for most asymptomatic infants with stable renal function. Families should receive fever/UTI education and prompt urine testing for unexplained fever. Low-dose continuous antibiotic prophylaxis is used variably in infancy or high-risk dilation, but its benefit is uncertain and no POM-specific randomized evidence establishes an optimal drug or duration. Suggested NCIT concepts are Active Surveillance and Antibiotic Prophylaxis. (ortiz2018longtermoutcomesin pages 1-2)
Accepted indications include recurrent/febrile UTI despite appropriate management, pain, stones or hematuria, progressive ureteral/collecting-system dilation, parenchymal thinning, DRF <40%, or a ≥5% fall in DRF. Delayed renographic drainage in an otherwise stable asymptomatic child is insufficient by itself. (boswell2024advancementsinsurgical pages 2-4, aiello2022efficacyandsafety pages 1-2)
Open ureteroneocystostomy with excision of the adynamic distal segment, with or without ureteral tapering/tailoring, remains the traditional definitive operation. Reported success is approximately 90–96%. It is technically more difficult in infants because a markedly dilated ureter must be implanted into a small bladder; potential complications include secondary obstruction, reflux, bladder dysfunction, and surgical morbidity. Suggested NCIT interventions are Ureteral Reimplantation, Ureteroneocystostomy, and Ureteroplasty. (ortiz2018longtermoutcomesin pages 4-5, aiello2022efficacyandsafety pages 1-2)
HPBD/EBD dilates the stenotic UVJ, generally followed by temporary ureteral stenting. A 2022 systematic review of 13 retrospective studies reported success rates of 69–100%, avoidance of open surgery in up to 77%, and complication rates of 0–50%, mainly infection- or stent-related. Its exact abstract conclusion states: “the overall level of evidence for HPBD is still low and further comparative studies or randomized clinical trials are needed.” (aiello2022efficacyandsafety pages 1-2)
In the largest long-term series, 100 POM units were treated and 79 with adequate follow-up analyzed. Median operative age was four months, median operating time 20 minutes, and median hospital stay one day. Long-term success was 87.3%; secondary VUR occurred in 21.5%, restenosis in 12.2%, and 12.7% ultimately required reimplantation. Repeat dilation successfully treated 8/9 restenoses, while endoscopic injection treated 13/17 secondary VUR cases. The authors concluded: “EBD may be considered first-line treatment in POM.” (ortiz2018longtermoutcomesin pages 1-2, ortiz2018longtermoutcomesin pages 4-5)
A 2024 retrospective comparison of 23 children evaluated cystoscopic-only versus radiologically controlled balloon dilation. Cystoscopic-only treatment had shorter operating time (30 versus 78 minutes; p=0.001), shorter hospitalization (one versus two days; p=0.009), and reported long-term success of 100% versus 71%, without more complications. The small, nonrandomized design precludes definitive superiority, but it supports a radiation-sparing implementation. (cayon2024comparativestudyof pages 1-2)
Robotic/laparoscopic reimplantation is increasingly used in specialized centers. Published series report approximately 91–97% success, but patient selection, follow-up, and surgeon learning curves vary. The 2024 expert conclusion is that endoscopic and minimally invasive procedures dominate recent literature but still require collaborative prospective comparison. (boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 4-5)
Nephrostomy, cutaneous ureterostomy, or internal stenting can decompress severe infection, renal failure, solitary-kidney obstruction, or technically difficult infant anatomy. Stents can cause UTI, migration, hematuria, and stones; a review summarized a roughly 40% stent-period problem rate in one longer-term series. (boswell2024advancementsinsurgical pages 2-4)
No gene therapy, cell therapy, RNA therapy, immunotherapy, molecularly targeted drug, or genotype-guided treatment exists. There is no relevant pharmacogenomic guidance.
Primary prevention is not currently possible because no modifiable POM-specific cause has been established. Prenatal ultrasound provides secondary prevention through early recognition, postnatal confirmation, and renal-function surveillance. Tertiary prevention consists of rapid treatment of febrile UTI, monitoring of dilation and DRF, selective prophylactic antibiotics, and timely decompression/reconstruction before irreversible renal injury.
Routine population carrier screening, cascade testing, preimplantation testing, or disease-specific prenatal molecular diagnosis is unsupported because no validated causal gene has been established. Genetic counseling is appropriate when disease is familial, bilateral, syndromic, or associated with additional CAKUT. Vaccination has no disease-specific preventive role.
No well-validated naturally occurring veterinary counterpart, breed predisposition, VBO annotation, or cross-species transmission issue was identified. The disorder is noninfectious and has no zoonotic potential. Sporadic hydroureter/megaureter may occur in animals as a structural urinary abnormality, but the retrieved evidence was insufficient to equate those cases with human primary congenital megaureter or assign conserved causal genes.
No dedicated mouse, rat, zebrafish, organoid, iPSC, or other model was identified as a validated model of isolated human POM. Developmental or knockout models that produce hydroureter can inform ureteral smooth-muscle differentiation and urinary-tract morphogenesis, but phenotypic similarity alone does not establish disease equivalence. No model currently supports drug screening or precision therapy for POM. This is a major research gap.
The relevant registered study is POMME, NCT05639283, a completed French retrospective observational study of 120 children treated for congenital obstructive megaureter. It was designed to identify operability factors rather than test an intervention; the registry was updated December 8, 2023. No relevant randomized drug, device, gene, RNA, or cell-therapy trial was identified. (NCT05639283 chunk 1)
Thus, current real-world innovation is procedural: better selection for surveillance, radiation-sparing endoscopy, HPBD, and laparoscopic/robotic reconstruction. The principal expert concern is evidence quality—heterogeneous definitions, retrospective single-center studies, variable follow-up, and inconsistent definitions of success. (aiello2022efficacyandsafety pages 6-7, boswell2024advancementsinsurgical pages 1-2, boswell2024advancementsinsurgical pages 2-4)
The strongest evidence concerns imaging, natural history, and surgery. Disease-specific epidemiology, quality of life, human genetics, molecular profiling, environmental causation, biomarkers, and animal models remain poorly characterized. Exact PMID values were not available in the retrieved records; DOI and registry URLs are therefore supplied rather than guessed. Ontology identifiers beyond directly supported MeSH D006869 should be verified against current HPO, MONDO, UBERON, GO, CL, NCIT, ICD, OMIM, and Orphanet releases before production use.
References
(boswell2024advancementsinsurgical pages 1-2): Timothy C. Boswell. Advancements in surgical management of megaureters. Current Urology Reports, 25:215-223, Jul 2024. URL: https://doi.org/10.1007/s11934-024-01214-8, doi:10.1007/s11934-024-01214-8. This article has 10 citations and is from a peer-reviewed journal.
(aiello2022efficacyandsafety pages 1-2): Giuseppe Aiello, Alessandro Morlacco, Marta Bianco, Matteo Soligo, Davide Meneghesso, Enrico Vidal, Waifro Rigamonti, and Fabrizio Dal Moro. Efficacy and safety of high-pressure balloon dilatation for primary obstructive megaureter in children: a systematic review. Frontiers in Urology, Nov 2022. URL: https://doi.org/10.3389/fruro.2022.1042689, doi:10.3389/fruro.2022.1042689. This article has 8 citations.
(ortiz2018longtermoutcomesin pages 1-2): Ruben Ortiz, Alberto Parente, Laura Perez-Egido, Laura Burgos, and José Maria Angulo. Long-term outcomes in primary obstructive megaureter treated by endoscopic balloon dilation. experience after 100 cases. Frontiers in Pediatrics, Oct 2018. URL: https://doi.org/10.3389/fped.2018.00275, doi:10.3389/fped.2018.00275. This article has 56 citations.
(boswell2024advancementsinsurgical pages 2-4): Timothy C. Boswell. Advancements in surgical management of megaureters. Current Urology Reports, 25:215-223, Jul 2024. URL: https://doi.org/10.1007/s11934-024-01214-8, doi:10.1007/s11934-024-01214-8. This article has 10 citations and is from a peer-reviewed journal.
(NCT05639283 chunk 1): Primary Obstructive Megaureter Management in Eastern Interregional Area. University Hospital, Strasbourg, France. 2020. ClinicalTrials.gov Identifier: NCT05639283
(shrateh2025bilateralprimarynonrefluxing pages 2-5): Oadi N. Shrateh, Sarah Nafea, Fahad Khan, Fawad Ali, Muhammad Faheem, and Naeem Sheikh. Bilateral primary nonrefluxing unobstructed megaureter in an adult: a case report and review of the literature. Journal of Medical Case Reports, Oct 2025. URL: https://doi.org/10.1186/s13256-025-05603-6, doi:10.1186/s13256-025-05603-6. This article has 3 citations and is from a peer-reviewed journal.
(morsoUnknownyearsupervidedbypr. pages 90-96): F MORSO, AA BELKHADEM, and A MEBKHOUT. Supervided by: pr. azzouni ms. Unknown journal, Unknown year.
(cayon2024comparativestudyof pages 1-2): J. González Cayón, A. Parente Hernández, A. Ramírez Calazans, V. Vargas Cruz, Á. Escassi Gil, and RM Paredes Esteban. Comparative study of cystoscopic control vs. radiological control in the endoscopic treatment of primary obstructive megaurater. Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica, 37 1:22-26, Jan 2024. URL: https://doi.org/10.54847/cp.2024.01.13, doi:10.54847/cp.2024.01.13. This article has 0 citations.
(isac2025predictivefactorsfor pages 1-2): George Vlad Isac and Nicolae Sebastian Ionescu. Predictive factors for spontaneous resolution in primary obstructive megaureter: the impact of hydronephrosis severity on clinical outcomes. Apr 2025. URL: https://doi.org/10.3390/jcm14072463, doi:10.3390/jcm14072463. This article has 4 citations.
(morsoUnknownyearsupervidedbypr. pages 29-32): F MORSO, AA BELKHADEM, and A MEBKHOUT. Supervided by: pr. azzouni ms. Unknown journal, Unknown year.
(isac2025predictivefactorsfor pages 10-12): George Vlad Isac and Nicolae Sebastian Ionescu. Predictive factors for spontaneous resolution in primary obstructive megaureter: the impact of hydronephrosis severity on clinical outcomes. Apr 2025. URL: https://doi.org/10.3390/jcm14072463, doi:10.3390/jcm14072463. This article has 4 citations.
(ortiz2018longtermoutcomesin pages 4-5): Ruben Ortiz, Alberto Parente, Laura Perez-Egido, Laura Burgos, and José Maria Angulo. Long-term outcomes in primary obstructive megaureter treated by endoscopic balloon dilation. experience after 100 cases. Frontiers in Pediatrics, Oct 2018. URL: https://doi.org/10.3389/fped.2018.00275, doi:10.3389/fped.2018.00275. This article has 56 citations.
(ortiz2018longtermoutcomesin pages 7-8): Ruben Ortiz, Alberto Parente, Laura Perez-Egido, Laura Burgos, and José Maria Angulo. Long-term outcomes in primary obstructive megaureter treated by endoscopic balloon dilation. experience after 100 cases. Frontiers in Pediatrics, Oct 2018. URL: https://doi.org/10.3389/fped.2018.00275, doi:10.3389/fped.2018.00275. This article has 56 citations.
(boswell2024advancementsinsurgical pages 4-5): Timothy C. Boswell. Advancements in surgical management of megaureters. Current Urology Reports, 25:215-223, Jul 2024. URL: https://doi.org/10.1007/s11934-024-01214-8, doi:10.1007/s11934-024-01214-8. This article has 10 citations and is from a peer-reviewed journal.
(mahmoud2024congenitalanomaliesof pages 1-2): Anfal Hussain Mahmoud, Iman M. Talaat, Abdelaziz Tlili, and Rifat Hamoudi. Congenital anomalies of the kidney and urinary tract. Jul 2024. URL: https://doi.org/10.3389/fmed.2024.1384676, doi:10.3389/fmed.2024.1384676. This article has 42 citations.
(aiello2022efficacyandsafety pages 6-7): Giuseppe Aiello, Alessandro Morlacco, Marta Bianco, Matteo Soligo, Davide Meneghesso, Enrico Vidal, Waifro Rigamonti, and Fabrizio Dal Moro. Efficacy and safety of high-pressure balloon dilatation for primary obstructive megaureter in children: a systematic review. Frontiers in Urology, Nov 2022. URL: https://doi.org/10.3389/fruro.2022.1042689, doi:10.3389/fruro.2022.1042689. This article has 8 citations.
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 7 |
| Resolved | 7 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 7 |
| On topic | 2 |
| Off topic | 0 |
All extracted references resolved successfully.